Tamoxifen and liver damage
Tamoxifen in the treatment of metastatic carcinoma of the breast is usually well tolerated with few side effects.' 2 We report on a patient in whom tamoxifen was associated with deterioration of liver function.
Case report
A 75 year old woman, who had undergone radical mastectomy in 1978 for breast carcinoma, developed bony metastases by April 1982 and was treated with tamoxifen 10 mg twice daily. Ten weeks later she developed nausea, vomiting, and hip pain due to progressive skeletal disease. Serum liver enzyme activities, serum calcium concentrations, and a liver scan were all normal. Prednisolone 5 mg twice daily was added to her treatment, but, despite regular antiemetics, nausea and vomiting persisted. Serum bilirubin concentration and aspartate aminotransferase activity continued to rise (figure). All drugs except diamorphine and prednisolone were stopped on 29 July, and aspartate aminotransferase activity and bilirubin concentration fell for two weeks (figure). Serological tests for hepatitis A During the next two months she remained well and measurements of aspartate aminotransferase and bilirubin continued in the upper normal range. She was readmitted in September for challenge with tamoxifen. After nine days of treatment aspartate aminotransferase activity had risen from a mean of 54 U/I before treatment to 79 U/l and nausea and vomiting had returned.
Tamoxifen was stopped after 12 days, and 24 hours later aspartate aminotransferase activity had risen to 258 U/l and bilirubin concentration to 31 Amol/l (1-8 mg/ 100 ml). Activity of alkaline phosphatase was raised throughout this period, which was consistent with metastatic bone disease. During the succeeding month the aspartate aminotransferase activity and bilirubin concentration fell towards normal, but she developed cerebral metastases and died on 9 November.
At necropsy the liver was small (823 g) and contained deposits of metastatic tumour, which were confirmed histologically. These measured up to 1-5 cm in diameter and were scattered throughout both lobes. No evidence was found of bile duct obstruction or gall stones.
Comment
One previous case has been reported in which tamoxifen was associated with cholestatic jaundice, but the patient refused liver biopsy and rechallenge with tamoxifen.3 We have observed two other patients with metastatic breast cancer in whom tamoxifen was suspected of causing impairment of liver function but in whom further investigations were not feasible. Imperial Chemical Industries, who manufacture tamoxifen, and the Committee on Safety of Medicines have not received any other reports of liver dysfunction.
Liver biopsy showed cholestasis, which is one of the most common signs of drug induced liver damage. Histologically, it is difficult to distinguish drug induced cholestasis from mechanical biliary obstruction; thus identification must depend largely on exclusion of possible causes of obstruction.
Our patient might have had hepatic metastases that were not detectable by the initial liver scan. In addition, she was taking other drugs (analgesics and steroids) that might have damaged the liver. There was, however, a close temporal relation between administration of tamoxifen and liver damage as indicated by a rise in activity of aspartate aminotransferase when the drug was started and a fall in activity when the drug was stopped. This relation was confirmed on rechallenge with tamoxifen, when enzyme activity again rose.
Liver damage attributable to tamoxifen appears to be extremely rare. We have observed it with certainty in only one of the 873 patients we have treated over the past 10 years, an incidence of only 0-1°o. This toxic effect does not detract from the value of tamoxifen in the management of metastatic breast cancer, but it may have relevance if tamoxifen becomes widely used as adjuvant treatment after mastectomy.
We thank Professor P J Scheuer for helpful comments on the liver biopsy specimens. A 21 year old policeman was admitted to hospital with progressive severe pain in his legs and feet of one week's duration. He had suffered from migraine for 10 years and had been taking methysergide (3 mg) and propranolol (120 mg) daily for two weeks. On examination his feet were pale, cold, and poorly perfused and only the femoral pulses were palpable in his legs.
Aortography disclosed extreme bilateral narrowing of the superficial femoral arteries consistent with severe spasm. Intravenous infusions of 10% dextran 40 in saline (Rheomacrodex) and heparin (500 units/hour) and a lumbar epidural block with 1 % lignocaine failed to afford any improvement.
Infusion of isoprenaline (1-2 ,fg/min) the next day resulted in mild improvement. Nevertheless, both feet gradually became gangrenous, and bilateral below knee amputations were performed six days after admission.
CASE 2
A 28 year old housewife was admitted complaining of excrutiating pain in her feet. On examination her feet were pale and cold. Her hands were also cold but of normal colour. Her carotid, axillary, and femoral pulses were the only palpable peripheral pulses. She had suffered from migraine and duodenal ulceration for some years and had taken numerous drugs including propoxyphene, benzodiazepine derivatives, diclofenac, cimetidine, chlordiazepoxide, raubasine, sucralfate, ergotamine tartrate, and oxprenolol. The precise dosages and duration of these treatments could not be established, but we ascertained that she had been taking oxprenolol and ergotamine tartrate tablets for a considerable time before admission. Arteriography showed severe spasm of most parts of the femoral arteries, the distal parts of the brachial arteries, and the radial arteries.
Intravenous infusion of heparin (500 units/hour) and dopamine (150-300 4g/min) resulted in moderate improvement in the circulation except in the left foot, which remained painful and developed a mottled appearance. A cannula was placed in the left femoral artery, and nitroglycerin (1 mg/hour) and heparin (500 units/hour) were infused. This caused a dramatic improve- 
